UCB (OTCMKTS:UCBJF) Sets New 1-Year Low – Time to Sell?

Shares of UCB SA (OTCMKTS:UCBJF) reached a new 52-week low on Thursday. The company traded as low as $219.60 and last traded at $219.60, with a volume of 1 shares changing hands. The stock had previously closed at $236.94.

Analysts Set New Price Targets

A number of research firms have recently commented on UCBJF. Piper Sandler restated a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd. Jefferies Financial Group upgraded UCB to a “hold” rating in a research report on Monday, August 3rd. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy”.

UCB Stock Performance

The stock has a fifty day moving average of $252.82 and a two-hundred day moving average of $279.78. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases, particularly in immunology and neurology. The company’s research and development activities target conditions such as inflammatory disorders, epilepsy, and other diseases affecting the central nervous system.

UCB’s portfolio includes Bimzelx (bimekizumab) for certain inflammatory conditions, Cimzia (certolizumab pegol) for immune-mediated diseases, and Fintepla (fenfluramine), Briviact (brivaracetam), Keppra (levetiracetam), and Nayzilam (midazolam) for seizure-related disorders.